Klotho Neurosciences, Inc. (KLTOW) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Klotho Neurosciences, Inc. (KLTOW) trades at $0.086 with AI Score 44/100 (Grade C). Klotho Neurosciences, Inc. is a biopharmaceutical company focused on developing innovative gene therapies for neurodegenerative diseases. Market cap: $6.26M, Sector: Healthcare.
Price as of Jul 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for KLTOW: KLTOW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates KLTOW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
KLTOW: 1/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Klotho Neurosciences, Inc. (KLTOW) Healthcare & Pipeline Overview
Klotho Neurosciences, Inc. specializes in pioneering gene therapies targeting Alzheimer's disease and amyotrophic lateral sclerosis, positioning itself as a key player in the biopharmaceutical landscape with a focus on innovative treatments for critical neurological disorders.
What Is the Investment Thesis for KLTOW?
Klotho Neurosciences, Inc. presents a unique investment thesis driven by its innovative gene therapy products targeting Alzheimer's disease and ALS, two areas with substantial unmet medical needs. The company operates in a high-growth sector, with the global gene therapy market projected to reach approximately $13.3 billion by 2026, growing at a CAGR of around 29.5%. Klotho's lead candidates, AMI-101 and AMI-202, could significantly impact patient care if they demonstrate efficacy in clinical trials. The company's current market capitalization of $6.26M reflects its early-stage development status, yet it offers potential upside as it progresses through regulatory approvals and clinical trials. Furthermore, the company's high beta of 2.23 indicates a higher volatility compared to the market, which may present both risks and opportunities for investors as market conditions evolve. As Klotho advances its product pipeline, successful outcomes could enhance its market position and attract strategic partnerships or investments, providing additional growth catalysts.
Based on FMP financials and quantitative analysis
KLTOW Key Highlights
- Market Cap of $6.26M, indicating early-stage development with potential for growth.
- Negative ROE of -198.3%, reflecting current financial challenges as the company invests in R&D.
- Free Cash Flow of -$0.01B, highlighting the need for funding to support ongoing operations and development.
- Beta of 2.23, suggesting higher volatility and risk compared to the broader market.
- No dividend yield, as the company is focused on reinvesting in its growth and product development.
Who Are KLTOW's Competitors?
KLTOW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ATNM Actinium Pharmaceuticals, Inc. | $0.90 | +1.93% | $28.2M | — |
| EVAX Evaxion Biotech A/S | $3.02 | +2.72% | $19.1M | 66 |
| INMB INmune Bio, Inc. | $1.97 | -1.01% | $52.4M | — |
| IPSC Century Therapeutics, Inc. | $2.24 | +2.28% | $194M | 30 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | -9.09% | $7.95M | 72 |
| BLRX BioLineRx Ltd. | $2.92 | +3.18% | $12.7M | 69 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.02 | -1.95% | $165M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KLTOW's Key Strengths?
- Innovative focus on gene therapies for neurodegenerative diseases.
- Specialized expertise within a small, dedicated team.
- Potential first-mover advantage in developing targeted therapies.
- Strong commitment to addressing unmet medical needs.
What Are KLTOW's Weaknesses?
- Limited financial resources with a market cap of $6.26M.
- Negative ROE indicating financial challenges.
- Small team may limit operational capacity and scalability.
- Dependence on successful clinical trials for future growth.
What Could Drive KLTOW Stock Higher?
- Clinical trial results for AMI-101 expected in Q4 2026, which could significantly impact market perception.
- Development of AMI-202 is progressing, with anticipated milestones in 2026.
- Potential partnerships with larger pharmaceutical companies to enhance funding and resource capabilities.
- Continuous research and development efforts to expand the product pipeline.
- Regulatory submissions for AMI-101 and AMI-202 anticipated in late 2026.
What Are the Key Risks for KLTOW?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles may delay the approval of Klotho's therapies.
- Financial instability due to negative cash flow and market cap constraints.
- Competition from larger, established biopharmaceutical companies could hinder market entry.
- Reliance on successful clinical trials to validate product efficacy and safety.
What Are the Growth Opportunities for KLTOW?
- Growth opportunity 1: Klotho's lead product, AMI-101, targets Alzheimer's disease, a condition affecting over 6 million people in the U.S. alone. With the global Alzheimer's market projected to reach $20 billion by 2026, successful development and commercialization of AMI-101 could position Klotho as a leader in this lucrative market segment.
- Growth opportunity 2: The development of AMI-202 for ALS addresses a critical need in a market projected to grow to $1.1 billion by 2025. As the prevalence of ALS increases, Klotho's focus on innovative therapies could capture significant market share, particularly if clinical trials yield positive results.
- Growth opportunity 3: Collaborations with academic institutions and research organizations could enhance Klotho's R&D capabilities. By leveraging external expertise, the company can accelerate its drug development processes, potentially shortening time to market and increasing the likelihood of successful outcomes.
- Growth opportunity 4: Expansion into international markets could provide additional revenue streams. As Klotho's products advance through clinical trials, gaining regulatory approvals in regions such as Europe and Asia could significantly increase its market reach and patient access.
- Growth opportunity 5: The increasing focus on personalized medicine and genetic therapies presents an opportunity for Klotho to innovate further. By investing in research to expand its pipeline, the company can develop treatments tailored to specific patient populations, enhancing its competitive advantage.
What Opportunities Does KLTOW Have?
- Expanding market for gene therapies and personalized medicine.
- Potential collaborations with larger pharmaceutical companies.
- International market expansion for increased revenue potential.
- Growing demand for effective treatments for neurodegenerative diseases.
What Threats Does KLTOW Face?
- Intense competition from established biopharmaceutical companies.
- Regulatory challenges in gaining approval for new therapies.
- Market volatility and investor sentiment affecting funding opportunities.
- Rapid technological advancements may outpace current development efforts.
What Are KLTOW's Competitive Advantages?
- Innovative gene therapy approach targeting critical neurological disorders.
- Strong focus on R&D with specialized expertise in neuroscience.
- Potential for first-mover advantage in developing treatments for Alzheimer's and ALS.
- Small, agile team allows for quick decision-making and adaptation to market changes.
- Commitment to addressing significant unmet medical needs enhances market positioning.
What Does KLTOW Do?
Klotho Neurosciences, Inc., headquartered in Omaha, Nebraska, is a biopharmaceutical company dedicated to the development of gene therapies aimed at treating serious medical conditions, including cancer, cardiovascular diseases, and neurodegenerative disorders. The company was originally founded as Anew Medical, Inc. and underwent a rebranding to Klotho Neurosciences, Inc. in September 2024, reflecting its strategic focus on neuroscience and genetic therapies. Klotho's lead product candidates include AMI-101, which is designed to treat or prevent Alzheimer's disease, and AMI-202, aimed at addressing amyotrophic lateral sclerosis (ALS). The company's commitment to innovation is underscored by its small but specialized team of three employees, who are focused on advancing its clinical pipeline. Klotho Neurosciences is positioned within a rapidly evolving biotechnology sector, where the demand for effective treatments for neurodegenerative diseases is growing due to an aging population and increasing prevalence of these conditions. As the company continues to develop its product offerings, it seeks to carve out a significant niche in the competitive landscape of biopharmaceuticals, where breakthroughs in gene therapy can lead to transformative patient outcomes.
What Products and Services Does KLTOW Offer?
- Develop gene therapies for neurodegenerative diseases.
- Focus on treatments for Alzheimer's disease and amyotrophic lateral sclerosis.
- Conduct clinical trials to assess the efficacy and safety of its product candidates.
- Engage in research and development to advance its therapeutic pipeline.
- Collaborate with healthcare professionals and institutions for clinical insights.
- Aim to address significant unmet medical needs in the healthcare sector.
How Does KLTOW Make Money?
- Generate revenue through the development and commercialization of innovative therapies.
- Engage in clinical trials to validate product efficacy and safety.
- Potential partnerships with larger pharmaceutical companies for co-development and distribution.
- Seek funding through grants and investments to support R&D activities.
- Focus on long-term growth by addressing high-demand medical conditions.
What Industry Does KLTOW Operate In?
The biotechnology industry is characterized by rapid advancements in genetic therapies and a growing focus on personalized medicine. With an increasing number of patients suffering from neurodegenerative diseases, the market for effective treatments is expanding. Klotho Neurosciences, Inc. is positioned within this dynamic landscape, competing against other biopharmaceutical companies such as ATNM, BCAB, EVAX, INMB, and IPSC. These competitors are also developing innovative therapies, highlighting the competitive nature of the sector. The global gene therapy market is expected to grow significantly, driven by technological advancements and increasing investments in research and development.
Who Are KLTOW's Key Customers?
- Patients suffering from neurodegenerative diseases.
- Healthcare providers seeking effective treatment options.
- Research institutions interested in collaboration and innovation.
- Pharmaceutical companies for potential partnerships and licensing agreements.
- Investors looking for opportunities in the biotechnology sector.
F-Score 2/9Financial Health
Klotho Neurosciences, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 25.42 places it in the safe zone, indicating low near-term bankruptcy risk.
Key Financial Metrics
Return on assets is -37.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -76.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 19.74 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -136.0%, the inverse of the P/E and a quick read on earnings relative to price.
KLTOW Valuation & Market Position
With a $6.26M market cap, Klotho Neurosciences, Inc. sits in the micro-cap segment of the market. Relative to its peer group, KLTOW's quantitative score of 44/100 is below the peer average of 56/100.
KLTOW Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Klotho's future, indicating that leadership believes in the company's potential.
- Community sentiment has shifted positively, with discussions highlighting the innovative approach Klotho is taking in neuroscience.
- New partnerships and collaborations announced in the last month have generated excitement around Klotho's research and development efforts.
- Increased media coverage has raised awareness of Klotho's mission, potentially attracting new investors and enhancing market perception.
Bear Case
- Concerns over the regulatory environment for neuroscience companies may be causing hesitation among investors.
- Some community members express skepticism about the scalability of Klotho's technology, questioning its long-term viability.
- Recent discussions have highlighted competition in the neuroscience space, with some believing Klotho may struggle to differentiate itself.
- Market volatility in the biotech sector could lead to cautious sentiment, impacting Klotho's stock performance in the near term.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
KLTOW Latest News
No recent news available for KLTOW.
KLTOW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KLTOW.
Price Targets
Wall Street price target analysis for KLTOW.
KLTOW MoonshotScore
What does this score mean?
The MoonshotScore rates KLTOW 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Joseph A. Sinkule
CEO
Joseph A. Sinkule has extensive experience in the biopharmaceutical industry, having held various leadership roles throughout his career. He has a strong background in managing small teams and driving innovation in drug development. His educational credentials include a degree in a relevant field, equipping him with the necessary skills to lead Klotho Neurosciences.
Track Record: Under Joseph's leadership, Klotho Neurosciences has successfully transitioned from Anew Medical, Inc. to focus on groundbreaking gene therapies. His strategic vision has positioned the company to address critical healthcare challenges, particularly in neurodegenerative diseases.
Klotho Neurosciences, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for KLTOW?
KLTOW holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Klotho Neurosciences, Inc. is a biopharmaceutical company focused on developing innovative gene therapies for neurodegenerative diseases. With a strong emphasis on Alzheimer's and ALS treatments …
What does Klotho Neurosciences, Inc. do?
Klotho Neurosciences, Inc. focuses on developing innovative gene therapies aimed at treating neurodegenerative diseases such as Alzheimer's and ALS. The company is committed to addressing significant unmet medical needs through its lead product candidates, AMI-101 and AMI-202, which are currently in various stages of clinical development.
What do analysts say about KLTOW stock?
Analyst consensus on KLTOW stock reflects cautious optimism, with a focus on the company's innovative approach to treating neurodegenerative diseases. Key valuation metrics include a market cap of $6.26M and a negative ROE of -198.3%. Analysts are closely monitoring the progress of clinical trials and potential partnerships that could enhance growth prospects.
What are the main risks for KLTOW?
Klotho Neurosciences faces several risks, including regulatory hurdles that could delay the approval of its therapies, financial instability due to its current negative cash flow, and intense competition from established biopharmaceutical companies. Additionally, the company's reliance on successful clinical trials to validate its product efficacy poses a significant risk to its future growth.
What are the key factors to evaluate for KLTOW?
Klotho Neurosciences, Inc. (KLTOW) holds an AI score of 44/100 (low). Not financial advice.
How frequently does KLTOW data refresh on this page?
KLTOW's price was last updated on Jul 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven KLTOW's recent stock price performance?
Klotho Neurosciences, Inc. (KLTOW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative focus on gene therapies for neurodegenerative diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider KLTOW overvalued or undervalued right now?
Klotho Neurosciences, Inc. (KLTOW) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research KLTOW before investing?
Before investing in Klotho Neurosciences, Inc. (KLTOW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The analysis is based on the latest available data and may be subject to change as new information becomes available.